Nanchang University - The First Affiliated Hospital

Nanchang 330006

1 studies enrolling now · 2 studies all time

What they study most

End Stage Kidney Disease, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling